Opioid Guide for Personal Injury Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 12 min read

A comprehensive guide to all opioids prescribed in personal injury -- hydrocodone, oxycodone, tramadol, codeine, morphine, tapentadol, and buprenorphine -- covering DEA scheduling, morphine milligram equivalents, tapering protocols, and what each opioid signals in PI documentation.

Opioids are a class of analgesic medications that bind to mu, kappa, and delta opioid receptors in the central nervous system to produce potent pain relief. In personal injury cases, opioids are prescribed for moderate to severe acute pain and for specific chronic pain conditions where other analgesic classes have proven insufficient. The presence, duration, and type of opioid in a PI pharmacy record provides some of the most clinically significant documentation available for establishing injury severity.

• Opioids are DEA-scheduled controlled substances prescribed for moderate to severe pain in PI cases, and their presence documents physician-assessed pain severity exceeding what non-opioid analgesics can manage
• The class spans Schedule II (oxycodone, morphine, hydrocodone combinations >15 mg), Schedule III (hydrocodone combinations), Schedule IV (tramadol), and unscheduled formulations (buprenorphine for pain)
• Morphine milligram equivalents (MME) provide a standardized measure of opioid potency that attorneys can use to demonstrate pain severity objectively
• Current prescribing guidelines limit opioid duration and dosing, making long-term opioid prescriptions particularly powerful evidence of refractory pain
• LienScripts documents all opioid prescriptions through its pharmacy lien program with full fill date, quantity, prescriber, and MME tracking

DEA Scheduling and What It Means in PI

Every opioid carries a DEA schedule classification that reflects its abuse potential and accepted medical use. In PI documentation, the schedule level provides context for the physician's prescribing decision:

Schedule II (highest abuse potential with accepted medical use): Oxycodone, morphine, hydromorphone, fentanyl, methadone. These require a new prescription for each fill -- no refills allowed. Each fill represents a separate physician prescribing decision.

Schedule III: Combination products containing hydrocodone with acetaminophen (Vicodin, Norco) when containing 15 mg or less per unit. Up to 5 refills permitted.

Schedule IV: Tramadol. Lower abuse potential classification; up to 5 refills permitted.

The regulatory burden on the physician increases with each schedule level. A Schedule II opioid prescription requires the physician to generate a new prescription for every fill, accept prescribing liability, and document medical necessity at each encounter. This creates a robust documentation trail.

Comprehensive Comparison: All Opioids in PI Practice

MME Factor: Multiplier to convert to morphine milligram equivalents. Example: oxycodone 10 mg = 15 MME (10 x 1.5).

When Physicians Prescribe Each Opioid

Tramadol: The Conservative Starting Point

Tramadol is typically the first opioid prescribed in PI cases because it occupies the lowest DEA schedule (IV) among opioids and has a dual mechanism -- weak mu-agonist activity combined with serotonin and norepinephrine reuptake inhibition. Its prescription documents that the physician determined non-opioid analgesics (NSAIDs, acetaminophen) were insufficient, but the pain does not yet warrant a more potent Schedule II agent.

Hydrocodone: The PI Workhorse

Hydrocodone with acetaminophen (Norco, Vicodin) is the most commonly prescribed opioid in personal injury cases. It provides moderate analgesic potency with the added benefit of acetaminophen's synergistic pain relief. Its presence in the pharmacy record documents moderate to moderately severe pain requiring controlled-substance intervention.

Oxycodone: Potency Escalation

Oxycodone -- whether as immediate-release (Percocet) or extended-release (OxyContin) -- represents a potency escalation from hydrocodone. Its 1.5x MME conversion factor means it delivers 50% more analgesic potency milligram-for-milligram. A switch from hydrocodone to oxycodone in the pharmacy record documents that the patient's pain was not adequately controlled by the most commonly used opioid.

Morphine: Severe and Post-Surgical Pain

Morphine is the reference standard opioid. In PI cases, it is most commonly encountered in extended-release formulations for severe chronic pain or in the immediate post-surgical setting. Its presence documents pain severity at the highest levels of the analgesic spectrum.

Tapentadol: Dual-Mechanism for Complex Pain

Tapentadol combines mu-opioid agonist activity with norepinephrine reuptake inhibition, making it uniquely effective for pain with both nociceptive and neuropathic components. Its prescription signals that the physician identified a complex pain pattern requiring a dual-mechanism approach.

Buprenorphine: Chronic Pain and Opioid Transition

Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer for long-term pain management. In PI cases, it appears either as a chronic pain management tool (Belbuca, Butrans) or as part of an opioid transition strategy when the patient is being moved away from full-agonist opioids.

Morphine Milligram Equivalents: Objective Severity Measurement

MME provides attorneys with an objective, standardized measure of analgesic intensity that translates clinical prescribing decisions into numerical data. Current CDC guidelines flag concern at 50 MME/day and recommend avoiding exceeding 90 MME/day without justification.

Common PI examples:

• Hydrocodone 10/325, one tablet four times daily = 40 MME/day (moderate)
• Oxycodone 10 mg four times daily = 60 MME/day (significant)
• Morphine ER 30 mg twice daily + oxycodone 5 mg four times daily = 90 MME/day (high)

When a patient's daily MME exceeds guideline thresholds, it documents that the treating physician determined the pain severity warranted accepting the additional risks associated with higher-dose opioid therapy.

Tapering Protocols and What They Document

Modern opioid prescribing requires structured tapering when discontinuing therapy. A typical taper reduces the dose by 10-25% every 1-4 weeks. In PI documentation, a taper protocol demonstrates:

• The patient required opioid therapy long enough to develop physiological dependence (not addiction -- a normal pharmacological response)
• The physician is following evidence-based guidelines for opioid management
• The duration of opioid therapy corresponds to the duration of significant pain
• The taper timeline itself documents weeks to months of continued opioid need

Treatment Escalation Patterns and PI Documentation Value

Opioid escalation follows predictable clinical patterns:

• Non-opioid to tramadol -- Pain exceeds NSAID/acetaminophen capacity; first controlled substance needed
• Tramadol to hydrocodone -- Tramadol insufficient; moderate-potency full agonist required
• Hydrocodone to oxycodone -- Potency escalation; hydrocodone not controlling pain
• IR opioid to ER formulation -- Continuous pain requiring around-the-clock coverage, not just breakthrough management
• Oral opioid to transdermal -- Chronic severe pain with stable opioid requirements; typically opioid-tolerant patients
• Full agonist to buprenorphine -- Transition to safer long-term management; partial agonist with ceiling effect

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Every opioid prescription in a PI record represents a physician's documented clinical judgment that the patient's pain is severe enough to warrant the regulatory burden, monitoring requirements, and risk profile of controlled-substance prescribing. In today's prescribing environment, no physician takes this decision lightly."

Defense Challenges and Rebuttals

"The patient is just seeking drugs, not treating real pain"

Rebuttal: The pharmacy record shows prescriptions from the treating physician at regular clinical intervals, consistent with legitimate pain management. The prescriber accepted clinical and legal liability with each prescription. If the patient were drug-seeking, the record would show multiple prescribers, early refill requests, and other patterns that are absent in legitimate PI cases.

"Opioids should not be needed this long after the accident"

Rebuttal: The duration of opioid therapy reflects the treating physician's ongoing clinical assessment. Complex injuries -- disc herniations, multiple fractures, post-surgical recovery, CRPS -- commonly require opioid therapy for months. Each refill represents a renewed clinical determination of medical necessity.

"The patient should have been on non-opioid alternatives"

Rebuttal: The pharmacy record typically shows a progression from non-opioid to opioid therapy, documenting that alternatives were tried first. NSAIDs, muscle relaxants, anticonvulsants, and other non-opioid options were insufficient, and the physician escalated appropriately.

MERIT Documentation for Opioid Cases

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For opioid cases, the MERIT report provides MME calculations, prescribing timeline analysis, concurrent medication documentation, and tapering schedule documentation that transforms raw controlled-substance dispensing data into a clinically coherent narrative.